The scale of the problem is striking. Childhood obesity has risen sharply over recent decades, and with it the early onset of comorbid conditions. Autopsy studies of young people in New York City have revealed fatty liver changes in a substantial proportion of adolescents, while analyses of national survey data show that the prevalence of fatty liver disease among United States adolescents increased markedly between the late 1980s and 2010. Among children with obesity, the prevalence is far higher than in the general pediatric population, and longitudinal studies following children with fatty liver disease have documented progression to more severe forms even when patients received standard lifestyle advice. The disease, once considered an adult affliction, is now firmly established as a pediatric epidemic.

Understanding why fat builds up in a child’s liver requires looking at a tangled web of interacting factors. The review describes a pathophysiology shaped by hormonal, genetic, lifestyle, nutritional, and environmental dynamics. At the center sits insulin resistance, the metabolic fault line that connects obesity to organ damage. When insulin signaling falters, the liver receives a flood of fatty acids from enlarged, dysfunctional adipose tissue and simultaneously ramps up its own fat production through a process called de novo lipogenesis. Isotope tracing studies have shown that in people with fatty liver disease, the majority of liver fat is derived from these two sources rather than from dietary fat directly, and weight loss has been shown to restore the normal balance of fatty acid sources reaching the liver.

Genetics adds another layer of complexity. Variants of the PNPLA3 gene, which encodes an enzyme involved in fat turnover within liver cells, influence how aggressively the disease progresses. In Hispanic youth with obesity, researchers have found that PNPLA3 genotype interacts with dietary intake of arachidonic acid and unsaturated fats to shape the degree of liver fibrosis, the scarring that marks advanced disease. Studies of Latino adolescents have similarly shown that the relationship between dietary sugars and liver stiffness differs depending on PNPLA3 status and disease severity. These findings help explain why children with similar diets and body weights can follow strikingly different disease trajectories, and why ethnic differences in metabolic and histologic features of the disease have emerged across populations.

The most consequential claim in the review concerns the heart. Large meta-analyses in adults have established that fatty liver disease increases the risk of both fatal and non-fatal cardiovascular events, and more recent work suggests the association extends to atrial fibrillation. Crucially, the review emphasizes that MASLD appears to confer cardiovascular risk independently of the traditional culprits. Research tracking children with fatty liver disease has documented higher rates of high blood pressure over time, and landmark follow-up studies have shown that cardiovascular risk factors measured in childhood predict adult cardiovascular events decades later. In other words, a fatty liver in a ten-year-old may be seeding the arteries of a forty-year-old, long before any symptom appears.

The mechanisms connecting a fat-laden liver to an ailing heart are increasingly well mapped. Excess hepatic fat promotes the release of inflammatory signaling molecules, including interleukin-6, which drives production of C-reactive protein, a marker of systemic inflammation and atherosclerosis. Oxidative stress, generated when overloaded mitochondria and lipid-processing machinery spill reactive molecules, damages blood vessel walls and modifies low-density lipoprotein particles into forms that are more likely to lodge in arterial plaque. Studies of mesenteric fat have shown that lipolysis in abdominal fat depots directly feeds hepatic steatosis and insulin resistance, creating a self-reinforcing loop between the gut, the liver, and the circulation. Mitochondrial dysfunction, a hallmark of the diseased liver, has also been implicated in endothelial dysfunction, the earliest measurable step on the road to heart disease.

Diagnosis remains one of the field’s most stubborn challenges. The gold standard, liver biopsy, is invasive, painful, and subject to sampling variability, making it poorly suited for screening large numbers of children. Imaging-based alternatives such as magnetic resonance imaging-derived proton density fat fraction and magnetic resonance elastography offer quantitative measures of liver fat and stiffness, and a relative decline of thirty percent in MRI-based fat fraction has been shown to predict fibrosis regression. But these tools are expensive and not universally available. The review highlights a growing arsenal of blood-based biomarkers under investigation, including cytokeratin-18 fragments, the enhanced liver fibrosis test, the ratio of fibroblast growth factor-21 to adiponectin, uric acid, soluble CD163, and the proteins LECT2 and pigment epithelium-derived factor. Gut microbiome signatures detected through metagenomic sequencing have also shown promise for identifying advanced fibrosis without a needle.

Treatment is where the picture becomes sobering. The review states plainly that there are currently no approved medications or other specific therapies for pediatric MASLD. Early stages of the disease are potentially reversible through lifestyle modification, particularly changes in diet and physical activity, but these strategies are notoriously difficult to implement and sustain in children and families over time. The evidence base for dietary intervention is nonetheless encouraging. Randomized trials in adolescent boys showed that a diet low in free sugar significantly improved fatty liver disease, and controlled feeding studies demonstrated that fructose restriction reduces hepatic de novo lipogenesis and improves insulin kinetics in children with obesity. A diet emphasizing a low ratio of omega-6 to omega-3 polyunsaturated fatty acids has also shown benefit, and docosahexaenoic acid supplementation decreased liver fat in a double-blind randomized trial of affected children.

Pharmacological options are emerging but remain unproven in children. Vitamin E and metformin failed to produce decisive histological benefit in a major pediatric trial, and cysteamine bitartrate improved liver enzymes without reducing disease activity scores. In adults, a phase 3 trial of the thyroid hormone receptor agonist resmetirom showed benefit in steatohepatitis with liver fibrosis, and glucagon-like peptide-1 receptor agonists such as semaglutide have advanced through late-stage testing, while liraglutide has been approved for obesity in younger children based on randomized trial evidence. Pilot work with the antioxidant N-acetyl cysteine in children with MASLD suggests another possible avenue. For adolescents with severe obesity, bariatric surgery has produced striking results, with studies linking surgical weight loss to resolution of fatty liver disease and reduced long-term liver and cardiovascular risk, and five- and ten-year outcome data from adolescent gastric bypass cohorts now available.

The authors close with a call for a comprehensive, multipronged approach to detection, monitoring, and management, one that treats the child’s liver and cardiovascular system as a single continuum rather than separate specialties. They hope the review will stimulate new research into MASLD and its broader cardiometabolic implications in pediatric populations, from validated noninvasive risk assessment tools to therapies designed specifically for growing bodies. With childhood obesity continuing to climb and no approved drug on the horizon, the message for clinicians and families alike is that the window for reversal opens early and narrows with time, and that a fatty liver detected in childhood may be the clearest early warning sign of the heart disease of tomorrow.

Subject of Research: Cardiometabolic perspectives and treatments for metabolic dysfunction-associated steatotic liver disease in children

Article Title: Metabolic dysfunction-associated steatotic liver disease—a review of the cardiometabolic perspectives and treatments in children

Article References: McGoogan, K., Hegde, V., Wilburn, J., Cooper, F., Gurnurkar, S., Prado, W. L., & Balagopal, P. B. (2026). Metabolic dysfunction-associated steatotic liver disease—a review of the cardiometabolic perspectives and treatments in children. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02101-7

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02101-7

Keywords: MASLD, pediatric fatty liver disease, childhood obesity, cardiovascular risk, insulin resistance, liver fibrosis, PNPLA3, biomarkers, lifestyle intervention, glucagon-like peptide-1 agonists, bariatric surgery, oxidative stress